Ching-Lin Hsieh

Feb 20, 2024 | nature.com | Ching-Lin Hsieh |Sarah R. Leist |John Powers |Jonathan C. Schisler |Ralph S Baric |Alexandra L. Tse

AbstractEver-evolving SARS-CoV-2 variants of concern (VOCs) have diminished the effectiveness of therapeutic antibodies and vaccines. Developing a coronavirus vaccine that offers a greater breadth of protection against current and future VOCs would eliminate the need to reformulate COVID-19 vaccines. Here, we rationally engineer the sequence-conserved S2 subunit of the SARS-CoV-2 spike protein and characterize the resulting S2-only antigens.

Dec 10, 2023 | nature.com | Ching-Lin Hsieh |Andrew Horton |Xuping Xie |Hongjie Xia |Pei-Yong Shi |Andrew D Ellington | +7 more

AbstractThe ongoing evolution of SARS-CoV-2 into more easily transmissible and infectious variants has provided unprecedented insight into mutations enabling immune escape. Understanding how these mutations affect the dynamics of antibody-antigen interactions is crucial to the development of broadly protective antibodies and vaccines. Here we report the characterization of a potent neutralizing antibody (N3-1) identified from a COVID-19 patient during the first disease wave.